09966.HK
Alphamab Oncology
HKSE · Healthcare · Biotechnology · CN
HKD 8.77
−1.02%Margins
Gross margin
85.9%
EBITDA margin
8.7%
EBIT margin
-0.6%
Net margin
4.5%
FCF margin
-11.8%
3.5%
Return on equity
2.7%
Return on assets
-0.4%
Return on invested capital
0.61x
Asset turnover
-HKD 142.1M
Cash from operations
HKD 1.74
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026